Payment overview · 2025
General Payments
$642.20
28 reported records · 17 companies
Healthcare provider profile · identity verified
Rhonda Davis White, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ATLANTA, GA · NPI 1922096510
Verified facts
What the public records show
CMS Open Payments records show Rhonda Davis White, NP received $642.20 in general payments during 2025 across 28 reported records.
UCB, Inc. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $81.52 | 12.7% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $65.85 | 10.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $60.03 | 9.3% | 3 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $55.39 | 8.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.05 | 8.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $47.86 | 7.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.65 | 7.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.11 | 6.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.05 | 5.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $28.16 | 4.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.54 | 3.7% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $22.94 | 3.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.65 | 3.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.24 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.91 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.50 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.75 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $642.20 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $65.85 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $60.03 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $55.39 | 2 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $47.86 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $37.82 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $34.05 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 63 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 44 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 30 | 16 |
| Omeprazole | Omeprazole | 27 | 12 |
| Losartan Potassium | Losartan Potassium | 25 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Meloxicam | Meloxicam | 17 | 14 |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Azithromycin | Azithromycin | 16 | 16 |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Simvastatin | Simvastatin | 12 | suppressed |
| Lisinopril | Lisinopril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $642.20 · 28 records | UCB, Inc. | AREXVY, AUSTEDO XR, BENLYSTA, Bimzelx, Cologuard Collection Kit, ENBREL, HYQVIA, KISUNLA, Kerendia, LEQEMBI, MOUNJARO, OTEZLA, Rystiggo, SHINGRIX, TREMFYA, TZIELD, VYEPTI, VYVGART HYTRULO, WAKIX, XYWAV | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error